Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is set to announce its earnings results after the market closes on Tuesday, October 29th. Analysts expect the company to announce earnings of ($1.53) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.02). The firm had revenue of $8.65 million for the quarter, compared to analysts’ expectations of $8.85 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. Sage Therapeutics’s revenue was up 249.8% compared to the same quarter last year. During the same period last year, the firm earned ($2.68) EPS. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Sage Therapeutics Price Performance
Shares of NASDAQ:SAGE opened at $8.01 on Monday. The business’s 50 day simple moving average is $7.53 and its 200-day simple moving average is $10.10. The firm has a market capitalization of $482.06 million, a price-to-earnings ratio of -0.95 and a beta of 0.91. Sage Therapeutics has a 12 month low of $5.84 and a 12 month high of $28.26.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on Sage Therapeutics
Sage Therapeutics Company Profile
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Featured Articles
- Five stocks we like better than Sage Therapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Are Growth Stocks and Investing in Them
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Golden Cross Stocks: Pattern, Examples and Charts
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.